Company Overview
Snapshot
Founded in January 2020 by Omer Zarchi and Nir Zarchi, Nervio operates with 11–50 employees. The company has raised $6.75M across two funding rounds from two investors. In December 2024, Nervio secured a grant from the Israel Innovation Authority.
Business overview
Nervio is a digital health startup that leverages data science and artificial intelligence in neurophysiology. The company's core technology is an AI-powered neuromonitoring solution designed to prevent avoidable paralysis and severe neurological complications during surgeries. This system provides real-time alerts to clinicians in the operating room, aiming to minimize permanent nerve injuries. Nervio operates in the Health Tech & Life Sciences sector, specifically within Digital Healthcare and Medical Decision Support, serving healthcare providers in markets such as North America and Europe.
Strategic signal
In December 2024, Nervio appointed Dr. Richard Vogel as its US CEO. This strategic leadership addition signals a clear intent for market expansion and strengthening its presence in the United States, indicating a focus on scaling operations and commercialization in a key global healthcare market.
Log in to access full profile ›Company Intelligence Q&A
- What is Nervio's primary mission?
- Nervio's mission is to prevent avoidable paralysis and severe neurological complications during surgeries by applying data science and artificial intelligence in neurophysiology.
- When was Nervio founded and by whom?
- Nervio was founded in January 2020 by Omer Zarchi and Nir Zarchi.
- What significant leadership appointment did Nervio make in December 2024?
- In December 2024, Nervio appointed Dr. Richard Vogel as its US CEO, signaling a strategic focus on the US market.
- What type of funding did Nervio receive in December 2024?
- This non-equity funding event was publicly disclosed.
- Which program selected Nervio in July 2023?
- In July 2023, Nervio was among 10 Israeli companies selected for Assuta's 'RISE With US' program.